Following the finding of a reduction in the activated partial thromboplastin time in various clinical conditions, including thrombosis, carcinoma, and acute haemorrhage, in the absence of anticoagulant therapy (Eastham and Morgan, 1964) , a reduction in the activated partial thromboplastin time relative to the corresponding prothrombin ratio persisting in patients with venous thrombosis during longterm oral anticoagulant therapy was noted (Eastham, 1968) . Later unsatisfactory attempts were made to define this finding using linear correlations between the prothrombin ratio and activated partial thromboplastin time (Eastham, 1970) and their ratios (Eastham, 1971 
Patients
Six thousand, three hundred and seventy-eight pairs of prothrombin ratios and their corresponding activated partial thromboplastin times were estimated in platelet-poor plasma samples taken from 446
Received for publication 19 November 1974. patients treated for more than 4500 patient/months during the six years 1967-1972.
Methods
Warfarin (or phenindione in the early stages of the series) was given to maintain the activated partial thromboplastin time within a range of 50 to 70 seconds, using bentonite as surface activator with soya bean extract as platelet substrate substitute (Eastham, 1968) . The prothrombin ratio was estimated, using rabbit brain thromboplastin (Diagen), which gave a range of 1-3 to 2-1 corresponding to the recommended range of 1 8 to 3 0 of the British comparative thromboplastin, samples of which were used regularly as references during the six years (Poller, 1970 
Discussion
After the initial finding of a reduction below normal in the activated partial thromboplastin time following thrombosis or acute haemorrhage or in patients with carcinoma (Eastham and Morgan, 1964 ) the decrease in the activated partial thromboplastin time relative to the corresponding prothrombin ratio in patients following venous thrombosis when compared with patients following myocardial infarction during long-term anticoagulant therapy (Eastham, 1968) suggested the possibility of laboratory assessment of the efficacy of such treatment, as distinct from the monitoring of anticoagulant dosage. This idea is supported by the present findings of a progressive 'shift to the left' of results from patients following venous thrombosis during treatment towards the pattern of distribution of results found in patients following myocardial infarction and patients with mitral valve disease on prophylactic anticoagulant therapy (fig 3, table H ). It has been known for some time that older patients are more liable to develop venous thrombosis, and it is interesting that the initial 'shift to the right' following venous thrombosis during the first 100 days of treatment is greater in the older age group (fig 4) .
The mechanisms whereby the activated partial thromboplastin time is reduced below the normal range after thrombosis and is reduced relative to the prothrombin ratio during anticoagulant therapy following venous thrombosis are not known. It is proposed to continue to analyse further results using the grid, to include a comparison of possible sex differences and also resistance to heparin, since resistance to heparin is increased after thrombosis (Eastham, Perham, and Pocock, 1972; O'Brien, Tulevski, Etherington, Madgwick, Alkjaersig, and Fletcher, 1974; Poller, 1960) .
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